First Patient with HSCT-TMA Completes Nomacopan Treatment in Phase 3 Trial
Photo courtesy of Towfiqu Barbhuiya on Unsplash

First Patient with HSCT-TMA Completes Nomacopan Treatment in Phase 3 Trial

  On July 7, 2022, biotechnology company Akari Therapeutics, Plc ("Akari") shared via news release that the first patient in its clinical trial has completed their course of treatment. Within…

Continue Reading First Patient with HSCT-TMA Completes Nomacopan Treatment in Phase 3 Trial
This Nonprofit’s Clinical Trial Committee Aims to Help Rett Syndrome Drug Development
source: pixabay.com

This Nonprofit’s Clinical Trial Committee Aims to Help Rett Syndrome Drug Development

According to a story from news-medical.net, the International Rett Syndrome Foundation (IRSF) has announced the launch of its Clinical Trial Committee. The committee was implemented with the goal of helping…

Continue Reading This Nonprofit’s Clinical Trial Committee Aims to Help Rett Syndrome Drug Development
FDA Lifts Clinical Hold on LB-001 IND for Methylmalonic Acidemia
Source: pixabay.com

FDA Lifts Clinical Hold on LB-001 IND for Methylmalonic Acidemia

During the Phase 1/2 SUNRISE clinical trial, which evaluated LB-001 for pediatric patients with methylmalonic acidemia, at least two participants experienced serious and severe adverse reactions: thrombotic microangiopathy. While investigating…

Continue Reading FDA Lifts Clinical Hold on LB-001 IND for Methylmalonic Acidemia
Phase 2b Global Trial for Idiopathic Pulmonary Fibrosis Has Completed Enrollment
https://pixabay.com/en/hand-world-ball-keep-child-earth-644145/

Phase 2b Global Trial for Idiopathic Pulmonary Fibrosis Has Completed Enrollment

Galecto has announced they have completed enrollment in their Phase2b trial which will investigate GB0139 as a treatment for idiopathic pulmonary fibrosis (IPF). This trial is called GALACTIC-1. Galecto anticipates…

Continue Reading Phase 2b Global Trial for Idiopathic Pulmonary Fibrosis Has Completed Enrollment
Update: Phase 3 Data Published on Ganaxalone for CDD
https://pixabay.com/en/books-stack-reading-read-education-933333/

Update: Phase 3 Data Published on Ganaxalone for CDD

According to a recent article in Businesswire, The Lancet has published data from the third phase of the Marigold trial. This clinical trial evaluated ganaxalone - marketed as ZTALMY - as a…

Continue Reading Update: Phase 3 Data Published on Ganaxalone for CDD